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Abstract Current non-invasive prenatal diagnosis for
fetal aneuploidies is based on biochemical and ultrasound
markers and needs to be improved in order to reduce the
number of pregnant women subjected to invasive
diagnostic procedures. Proteomic technologies allow for
new strategies for discovering biomarkers in complex
biological fluids in a high-throughput and sensitive
manner. Application of advance proteomic tools to
profile pathology-specific proteins in maternal plasma
obtained from pregnancies with aneuploid fetuses
revealed biomarker-candidates that can potentially revo-
lutionize the diagnostic and treatment procedure in favor
of better prediction and improved individual outcomes.
The current review focuses on studies of maternal
peripheral blood using proteomic technologies, describes
alterations noted in the presence of fetal aneuploidies and
discuss their potential use as biomarkers for non-invasive
prenatal diagnosis.
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Introduction
Chromosome aneuploidies and structural abnormalities are
a leading cause of developmental disabilities and congenital
malformations in man with an incidence of about one in
200 newborns [1].
The current approach for testing for fetal chromosome
abnormalities is cytogenetic analysis of fetal cells following
amniocentesis or chorionic villus sampling (CVS). These
diagnostic tests, which have an accuracy of approximately
99%, are most often used as a second line of study, due
to their invasiveness and relative risk for fetal loss. As
various studies have demonstrated, all women undergo-
ing invasive tests, only 1%–5% actually have an affected
fetus [2, 3].
In order to reduce, or even eliminate, unnecessary
invasive procedures screening tests for fetal chromosome
abnormalities have been developed. Prenatal screening
aims to estimate a woman’s risk of having an affected
fetus based on a combination of ultrasound markers and
the concentration of certain biomarkers [4]. Second-
trimester screening biomarkers for fetal aneuploidies,
known as «quad screening», involve maternal serum α-
fetoprotein (AFP), unconjugated estriol (uE3), human
chorionic gonadotropin (hCG) and inhibin A [5]. Screen-
ing in the first trimester of gestation involves nuchal
translucency measurement combined with maternal serum
hCG and PAPP-A. Despite intense efforts, the highest
detection rate obtained using prenatal screening techniques
G. T. Tsangaris is a National Representative of EPMA in Greece.
A. Kolialexi (*) :G. Tounta :A. Mavrou
Department of Medical Genetics, Aghia Sofia Children’s Hospital,
Athens University School of Medicine,
Thivon & Levadias,
115 27, Athens, Greece
e-mail: akolial@med.uoa.gr
A. K. Anagnostopoulos
Proteomics Research Unit, Centre of Basic Research II,
Biomedical Research Foundation, Academy of Athens,
Athens, Greece
A. Antsaklis :G. T. Tsangaris
1st Department of Obstetrics & Gynecology,
Athens University School of Medicine,
Athens, Greece
EPMA Journal (2011) 2:157–161
DOI 10.1007/s13167-011-0084-z
is 95% at a false positive rate of 5% and may be even lower if
certain screening techniques (e.g., nuchal translucency) are
not offered [5, 6]. Additionally, available screening tests for
fetal aneuploidies lack specificity. Patients who screen
positive are generally offered genetic counseling and
definitive diagnosis is recommended through invasive
procedures [7].
With regards to the early non-invasive prenatal detection
of fetal aneuploidies the need for and the development of
reliable serum biomarkers, which are both sensitive and
specific, remains a long awaited priority.
Recent advances in mass spectrometry based proteomic
technologies are transforming medical research [8, 9].
Proteomics involve the analysis and illumination of all
proteins encoded by the genome. It is these proteins that
can be pursued as biomarkers for non-invasive prenatal
diagnosis and possibly elucidate the molecular mechanisms
involved in fetal aneuploidies. Biomarkers represent spe-
cific biological conditions, including disease states and may
have potential roles at every step of disease management. In
contrast to genetic biomarkers, in the form of disease genes,
that are able to define the risk of developing a disease,
alterations of the proteome can be used for prediction, early
detection and diagnosis as well as disease prognosis,
progress monitoring and evaluation of response to therapy.
In addition to their direct use in tracking disease, proteomic
biomarkers can provide targets for therapeutic intervention
and advance knowledge about signaling pathways involved
in disease.
This review will explore the possibility of applying
proteomic technologies for the identification of novel
biomarkers that aim to improve prenatal screening tests
for fetal aneuploidies.
Source of biomarkers for non-invasive prenatal
diagnosis
Efforts for improvement of current screening include
several related biological fluids, such as maternal
peripheral blood, maternal urine or cervical-vaginal fluid
(CVF) that can be easily obtained using minimally invasive
procedures.
Urine has the advantage of being frequently and non-
invasively available, abundant and as a result of being a
filtrate of serum, relatively simple in its composition.
Although the protein complement of urine has been
characterized using various proteomics technologies, its
low protein content and high concentration in salts and
other contaminants represent a major challenge for the
routine quantitative studies required for biomarker dis-
covery [10–12]. Consequently, detection of proteins in
urine has received relatively little attention as a source of
potential biomarkers for fetal aneuploidies CVF is a
complex biological fluid that contains proteins predomi-
nantly synthesized by the endocervix and vaginal cells
[13]. Shaw et al. characterized the protein repertoire of
human CVF using two different fractionation approaches,
SDS-PAGE and strong cation exchange chromatography,
followed by LCMS/MS [14]. They identified 685 proteins
with extracellular or membrane proteins making up to
30% of the proteins identified. Dasari et al. compared the
CVF proteome with that of the AF and showed 77 proteins
unique to CVF, while 56 were also present in AF, due to
leakage of AF into CVF caused by disruption and
secretion of the chorionic-decidual interface [15]. Further
investigation, however, will be necessary in order to
explore the possibility of using CVF for diagnosis or
screening of aneuploidies.
Maternal peripheral blood has been frequently analyzed
in order to identify differentially expressed proteins for
pregnancy-related conditions [16–19]. This idea is mainly
based on the observation that the placenta from fetuses with
chromosomal aneuploidies is morphologically distinct from
that of euploid fetuses, a feature attributed to altered
aberrant protein expression. As the placenta is in direct
contact with maternal circulation, proteins released by it
can be detected in maternal plasma, and consequently serve
as promising markers for fetal aneuploidies.
For protein studies plasma is often preferred over
serum because it is obtained by bypassing the process of
clotting which activates proteases and degrades proteins
into fragments. It represents however the most complex
of human proteomes, due to the large dynamic range
(10 orders of magnitude) of individual protein concen-
trations [8]. The most abundant protein present in human
plasma is albumin at 35–50 mg/ml. The top 10 most
abundant proteins make up 90% of plasma proteins and
mask the presence of lower-abundance proteins. For this
reason depletion of the most abundant proteins and/or
prefractionation are recommended in order to observe the
less abundant ones [20]. Depletion can be performed
using various commercial kits mainly based on affinity
columns [7, 20, 21]. This approach, however, carries
certain disadvantages, as some of the high-abundance
proteins, albumin in particular, are known to act as carrier
molecules for other proteins and by removing them, poten-
tially interesting molecules may be lost as well [22, 23].
Prefractionation is usually performed using either two-
dimensional electrophoresis (2D-E) or liquid chromatogra-
phy (LC). 2D-E is the most commonly used proteomic
approach for biomarker discovery, due to its power to
separate proteins in a gel matrix based on two independent
physicochemical properties of each protein: the isoelectric
point (pI) and the molecular weight (MW) [24–26]. 2D-E
has the advantage of easy visualization of large numbers of
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proteins. When gels from different samples are compared, it
is possible to identify gel spots that differ between samples.
The main drawbacks of 2D-E include reproducibility, time
and labor intensiveness of the process and imperfect
separation of hydrophobic proteins in both Pi and MW
extremities.
Liquid chromatography (LC) is gaining in popularity
due its resolving power. Proteins are often first digested and
the resulting peptides are separated by chromatography,
based on a different characteristic, such as charge, followed
by another chromatographic separation based on another
property, such as hydrophobicity [27]. 2D-LC coupled to
tandem mass spectrometry (MS/MS) is now commonly
known as multi-dimensional protein identification technique
(MudPIT) [28].
Application of proteomics for prenatal biomarker
discovery
To date, several studies have analyzed maternal blood in
search for biomarkers for fetal aneuplodies using «top-down»
and «bottom-up» MS based proteomic technologies.
Most studies focused on DS, since it is the most common
congenital anomaly, with a prevalence of 1 in 732 births
[29].
The first attempt to identify biomarkers for DS was
performed using a combination of top-down and bottom-up
approaches such as DIGE, 2-dimensional liquid chroma-
tography chromatofocusing, MudPIT, LC/LC-MS/MS and
MALDI-TOF-MS peptide profiling (Table 1) [16]. First and
2nd trimester maternal serum from women carrying DS
fetuses and gestational age-matched controls, were ana-
lyzed. A list of 25 proteins differentially abundant in DS
serum was reported with an average recognition capability
that approached 96%.
Kolialexi et al. analyzed plasma from 8 women carrying
a DS fetus and from 12 women carrying chromosomally
normal ones, matched for gestational age, maternal age and
ethnicity, in the 2nd trimester of pregnancy, using 2-DE
coupled with MALDI-TOF-MS [17]. Gel comparison
revealed nine proteins differentially expressed in maternal
plasma in women with DS fetuses (Fig. 1). Eight proteins,
Transthyretin (TTHY), Ceruloplasmin (CERU), Afamin
(AFAM), Alpha-1-microglobulin (AMBP), Apolipoprotein
E (APOE), Serum amyloid P-component (SAMP),
Histidine-rich glycoprotein (HRG) and Alpha-1-antitrypsin
(A1AT) were up-regulated and one, Clusterin (CLUS),
down- regulated. All nine proteins detected in this study are
known to be involved in fetal growth and development,
while APOE, SAMP, AFAM and CLUS are associated with
the DS phenotype. All differentially expressed proteins are
candidate biomarkers for DS, providing opportunities for
the development of non-invasive prenatal diagnosis. In
another study, the same group compared the protein
composition of maternal plasma samples from pregnant
women with normal and Turner syndrome fetuses, using a
similar methodology [18]. The study showed nine proteins
(C1S, CO3, CLUS, AFAM, HABP2, IGHA1, HPT, SHBG,
and CD5L) significantly increased in the plasma of
women carrying TS fetuses, whereas KNG1, IGJ, and
TTHY were decreased.
Busch et al., using Surface-Enhanced Laser Desorption/
Ionization time of- flight mass spectrometry (SELDI-TOF)
technology, compared the proteomic profiles of first-trimester
serum samples from women carrying a normal fetus with
samples from cases carrying a fetus with DS [30]. Following
bio-informatic analysis, a combined pattern of six peaks was
found to predict discrimination between the two groups of
mothers with 91% sensitivity and 97% specificity. Lack of
precise protein identification in SELDI-TOF, however, limits
the information about these biomarkers to their m/z value.
Table 1 Summary of biomarkers for fetal aneuploidies identified in maternal plasma using different proteomic technologies
Chromosomal abnormality Proteomic technology Biomarkers Reference
Down Syndrome MudPIT, LC/LC -MS,
MALDI-TOF-MS
A1AG1, A1AG2, A1BG, A2GL, AFAM, APOA1, APOA4, APOC2,
APOC3, APOC, CFAH, APOE, CFAI, CLUS, CO3, FETUA, HRG,
ITIH4, KNG1, PLMN, PSG1, RETBP, SHBG, TETN, TTHY
[16]
Down Syndrome 2-DE, MALDI-TOF-MS TTHY, CERU, AFAM, AMBP, APOE, SAMP, HRG, A1AT and CLU, [17]
Down Syndrome SELDI-TOF 6 characteristic peaks [30]
Down Syndrome iTRAQ, MALDI TOF/TOF PZP, C4BPA, LAC1, CGHB, BTD, IGKC, IGHG2,GLHA, PHLD,
IGHG3, FETUB, ALS, HGFL, FINC, CO5, CO8B, SAMP,
GBG, HEMO, THRB, ITIH4, APBB1, CFAH, HPT, PROZ,
CPN2, CO8A, CRP, A1AT, ALBU, ACTG, APOM,
APOA4, CXCL7, APOA1, A2MG, TRFE, VWF,
FIBA, CO3, PGBM, LUM, APOB, TITIN, APOA,
AFAM, GELS, DYH9, APOH and PRDX2
[19]
Turner syndrome 2-DE, MALDI-TOF-MS C1S, CO3, CLUS, AFAM, HABP2, IGHA1, HPT, SHBG,
CD5L, KNG1, IGJ, and TTHY
[18]
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Recently, Kolla et al. used four-plex iTRAQ labeling
to compare six 1st trimester maternal plasma samples
from women known to carry DS fetuses [19]. Analysis
revealed 50 proteins, with a variety of functions and
expression levels, differentially expressed in DS fetuses.
Further verification of these proteins may reveal
potential biomarkers which could improve current
screening.
Concluding remarks and outlook
Proteomic studies that explore proteins released by the
fetus into the maternal circulation offer new opportu-
nities for the identification of either one protein marker
or a panel of markers for non-invasive prenatal
diagnosis that could be usefully employed for diag-
nostic purposes or improvement of the current screening
methods.
It is important to note that experimental design using
standard protocols, followed by appropriate analytical
techniques and statistical analysis, are critical to proteo-
mic experiments. In complex samples, such as peripheral
blood, use of analytical techniques that allow rapid
screening and require small quantity of sample for
accurate protein identification are of great importance.
Of equal importance is the use of protocols that
guarantee identical sample collection and proper storage
conditions to ensure reproducibility. Emphasis should be
placed on sample purification, protein digestion plus
affinity capture and sample fractionation to reduce the
complexity of the target biological fluid. It must also be
noted that, when identifying biomarkers for prenatal
diagnosis, gestational age-matched controls must be used,
since proteins content depend on the developmental stage
of the fetus.
Regardless of the method used as the first step of
biomarker discovery process, the resulting candidate
markers need to be further proved and tested if they are to
become clinically used biomarkers. Candidates need to be
further qualified, in order to confirm their differential
abundance in the tested samples, in a targeted manner, in
a statistically significant number of samples. Unfortunately,
antibodies against these newly discovered candidates are
frequently unavailable, and alternatives to immunoassays
should be used [31].
Finally, before any meaningful application of these
proteomic biomarkers, a clinical assay should be devel-
oped and extensive validation in the form of well-
designed, statistically significant human clinical trials
must be performed. Validation should also involve large
scale multicenter clinical trials to ensure the sensitivity
and specificity required for prenatal diagnosis. It is
important to compare the sensitivity and specificity of
the new biomarkers for population screening with those
of the currently available tests for the detection of
pregnancies at risk for fetal anuploidies. Thus the
collection of biological samples, along with clinical,













































Fig. 1 2D-E regions including spots with different intensity in maternal plasma samples from women known to carry normal and DS fetuses.
Differentially expressed spots correspond to Apo E and SAMP (From [17] copyright Willey. reproduced with permission)
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